Successful Booster Antibody Response up to 54 Months after Single Primary Vaccination with Virosome-Formulated, Aluminum-Free Hepatitis A Vaccine | Zendy

B. R. Beck | Zendy; Christoph Hatz | Zendy; R Brönnimann | Zendy; Christian Herzog | Zendy

Open Access

Successful Booster Antibody Response up to 54 Months after Single Primary Vaccination with Virosome-Formulated, Aluminum-Free Hepatitis A Vaccine

Author(s) -

B. R. Beck,

Christoph Hatz,

R Brönnimann,

Christian Herzog

Publication year - 2003

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/378890

Subject(s) - medicine , hepatitis a vaccine , immunogenicity , booster dose , booster (rocketry) , vaccination , titer , immunology , virology , hepatitis a , antibody , hepatitis , physics , astronomy

This study demonstrates that a booster dose of the virosome-formulated, aluminum-free hepatitis A vaccine Epaxal (Berna Biotech) is highly immunogenic in subjects who received a single primary dose of this vaccine 18-54 months earlier. There were no significant differences in geometric mean antibody titers (GMTs) among subjects who received the booster dose 18-29 months (GMT, 2330 mIU/mL), 30-41 months (GMT, 2395 mIU/mL), or 42-54 months (GMT, 2432 mIU/mL) after primary vaccination, indicating that delays in the administration of booster vaccination do not lead to a loss of immunogenicity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research